CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 228 enrolled
Drug / intervention
Talquetamab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04586426
NCT04586426Phase 2Active
CompareCT.gov

A Phase 1b/2 Dose Escalation and Expansion Study of the Combination of the Bispecific T Cell Redirection Antibodies Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Janssen Research & Development, LLC·interventional·Posted Oct 14, 2020·Updated Jan 16, 2026

In Brief

A Phase 2 clinical trial evaluating Talquetamab and Teclistamab for Multiple Myeloma. Active but no longer recruiting, targeting 228 participants across 40 sites in 7 countries.

Detailed Summary

The purpose of this study is to identify the recommended Phase 2 regimen(s) (RP2R\[s\]) and schedule for the study treatment (Part 1), to characterize the safety of the RP2R(s) for the study treatment (Part 2) and to evaluate the anticancer activity of talquetamab + teclistamab in participants with relapsed or refractory multiple myeloma and extramedullary disease (EMD) (Part 3).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesAustralia, Canada, Israel, Japan, South Korea, Spain, United States
Collaborators--

Timeline

Phase 2Active
202120222023202420252026
First PostedOct 14, 2020
Enrollment StartDec 15, 2020
Primary CompletionMar 18, 2025
Study CompletionOct 27, 2026
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 5.7 years ago

Interventions

Talquetamabdrug

Talquetamab will be administered by subcutaneous (SC) injection.

Teclistamabdrug

Teclistamab will be administered by SC injection.